Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ME2 | P23368 | 1/20 | 0.50 |
| ▸ | ME1 | P48163 | 1/20 | 0.50 |
| ▸ | ME3 | Q16798 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16825901 | 1.00 | MEN1 (0.62) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL16826097 | 0.88 | ALDH1A1 (0.64) | MEN1KMT2AMAPTHTTGAA | |
| SCHEMBL16826096 | 0.88 | ALDH1A1 (0.64) | MEN1KMT2AMAPTHTTGAA | |
| SCHEMBL16826357 | 0.88 | ALDH1A1 (0.60) | MEN1KMT2AMAPTHTTGAA | |
| SCHEMBL16826162 | 0.88 | ALDH1A1 (0.60) | MEN1KMT2AMAPTHTTGAA | |
| SCHEMBL16825670 | 0.88 | NPC1 (0.60) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL16825667 | 0.88 | NPC1 (0.60) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL10721826 | 0.79 | MEN1 (1.00) | MEN1KMT2AMAPTUSP2GAA | |
| SCHEMBL6896101 | 0.77 | MEN1 (0.77) | MEN1KMT2AMAPTUSP2GAA | |
| SCHEMBL16825949 | 0.77 | HRH3 (0.51) | MEN1KMT2AMAPTHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3082805-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | The Institute For Drug Delivery (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | MEN1 2231/4885KMT2A 1919/4885MAPT 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.